TMOThermo Fisher Scientific demonstrates robust financial health and a strong market position, driven by essential services in life sciences and diagnostics. While its valuation may appear high on some metrics, its consistent performance and broad market reach support a positive long-term outlook. Technicals suggest a recent pullback, offering a potentially attractive entry point.
Thermo Fisher Scientific is a leader in critical areas of healthcare and scientific research, benefiting from sustained demand in life sciences, diagnostics, and biopharma services. Trends like increased healthcare spending, advancements in genetic research, and the need for reliable laboratory infrastructure provide strong secular tailwinds.
Thermo Fisher Scientific demonstrates strong financial performance with consistent revenue growth, healthy profitability, and a solid balance sheet. Its P/E ratio is elevated compared to its trailing performance, but forward estimates suggest continued earnings growth.
The stock has exhibited strong upward momentum, trading above key moving averages. However, current technical indicators suggest it might be nearing overbought territory, hinting at a potential short-term consolidation or minor pullback before resuming its uptrend.
| Factor | Score |
|---|---|
| Life Sciences & Healthcare Demand | 95 |
| Biotechnology & Pharmaceutical Services | 90 |
| Diagnostic & Testing Solutions | 85 |
| Technological Integration (AI/Digital) | 75 |
| Regulatory & Geopolitical Factors | 70 |
| Factor | Score |
|---|---|
| Valuation | 60 |
| Profitability | 85 |
| Growth | 78 |
| Balance Sheet Health | 75 |
| Cash Flow | 85 |
| Factor | Score |
|---|---|
| Trend Analysis | 85 |
| Momentum | 50 |
| Volume | 70 |
| Support & Resistance | 80 |
| Short-term Indicators | 65 |
Consistent EPS Beat
Thermo Fisher Scientific (TMO) has a history of beating earnings per share (EPS) estimates, with positive surprises in 11 out of the last 12 quarters. The most recent quarter showed a surprise of 0.93% (reported 5.15 vs. estimate 5.10).
Improving Financial Position
The company shows a strengthening financial position with total assets increasing from $95.12B in Q4 2021 to $97.32B in Q4 2024, while total liabilities decreased from $54.15B to $47.65B over the same period.
High Forward P/E Ratios
Quarterly P/E ratios for 2025 are significantly elevated (e.g., Q1 2025 at 124.5), suggesting very high growth expectations baked into the current stock price.
Mixed Short-Term Signals
In the short-term timeframes (e.g., 1-minute, 5-minute, 15-minute charts), many moving averages are showing 'Sell' signals, indicating potential short-term headwinds or a consolidation phase.
September 2025
15
Ex-Dividend Date
October 2025
15
Next Dividend Date
October 2025
22
Next Earnings Date
H: $5.63
A: $5.51
L: $5.47
H: 11.00B
A: 10.90B
L: 10.84B
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery and production of drugs and vaccines, as well as diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment includes clinical diagnostics offering liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics offers develops, manufactures, and markets complete blood test systems to support the clinical diagnosis and monitoring of allergy, asthma, and autoimmune diseases; microbiology offers dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; transplant diagnostics products include human leukocyte antigen typing and testing for organ transplant market; and healthcare market channel offers consumables, diagnostic kits and reagents, equipment, instruments, solutions, and services. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
552.63 USD
The 39 analysts offering 1 year price forecasts for TMO have a max estimate of 767.00 and a min estimate of 450.00.